



## **EMPHASIS-lung**

### **ETOP 3-12**


*A randomized phase III trial of erlotinib versus docetaxel in patients with advanced squamous cell non-small cell lung cancer who failed first line platinum-based doublet chemotherapy stratified by VeriStrat Good vs VeriStrat Poor*

**Erlotinib Maldi TOF Phase III Signature in Squamous cell non-small cell lung cancer**


A clinical trial of ETOP

NCT01652469


SAP VERSION	V.1
SAP VERSION DATE	07.01.2015
TRIAL STATISTICIAN	Urania Dafni
TRIAL PRIMARY INVESTIGATORS	Egbert Smit, Solange Peters
DSMB SAP AUTHOR	Marie Kassapian




**Figure 1:** Patient flowchart




**Figure 2a:** expected vs observed accrual




**Figure 2b:** Cumulative accrual by treatment arm




**Figure 3:** Time on follow-up by treatment arm (N=xxx)



**Figure 4:** Time on treatment by treatment arm ( $N=xxx$ )




**Figure 5a:** *Distribution of adverse events*




**Figure 5b:** Distribution of adverse events by treatment arm







**Figure 6a:** Distribution of serious adverse events




**Figure 6b:** Distribution of serious adverse events by treatment arm




**Figure 7a:** Distribution of serious adverse events




**Figure 7b:** Distribution of serious adverse events by treatment arm




**Figure 8a:** Distribution of serious adverse events according to CTCAE Version 4



**Figure 8b:** Distribution of serious adverse events by treatment arm according to CTCAE Version 4




**Figure 9a: Severity of adverse events**




**Figure 9b:** Severity of adverse events by treatment arm







**Figure 10a:** Severity of adverse events according to CTCAE Version 4




**Figure 10b:** Severity of adverse events by treatment arm according to CTCAE Version 4




**Figure 11a:** Maximum severity of adverse event per patient




**Figure 11b:** Maximum severity of adverse event per patient by treatment arm




**Figure 12a:** Distribution of adverse events



**Figure 12b:** Distribution of adverse events by treatment arm




**Figure 13a:** Distribution of adverse events according to CTCAE Version 4




**Figure 13b:** Distribution of adverse events by treatment arm according to CTCAE Version 4







**Figure 14:** Progression-free Survival (N=xxx)



**Figure 15:** Progression-free Survival by VeriStrat status (N=xxx)



**Figure 16: Overall Survival (N=xxx)**



**Figure 17:** Overall Survival by VeriStrat status (N=xxx)